FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1994839562> ?p ?o ?g. }

• W1994839562 endingPage "618" @default.
• W1994839562 startingPage "614" @default.
• W1994839562 abstract "Objectives: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptors with proven clinical benefit in patients with metastatic renal cell carcinoma (RCC). This phase I/II study investigated sunitinib in combination with an epidermal growth factor receptor inhibitor, gefitinib, in patients with metastatic RCC. Methods: In phase I, patients received sunitinib 37.5 or 50 mg in 6-week cycles (4 weeks on treatment, 2 off) plus gefitinib 250 mg, both once daily, to determine the sunitinib maximum tolerated dose (MTD). Pharmacokinetics was assessed for both drugs. In phase II, patients received sunitinib MTD plus gefitinib to evaluate the safety and antitumor activity of this combination. Results: Forty-two patients were enrolled: 11 in phase I, and 31 in phase II. In phase I, 2 dose-limiting toxicities were observed with sunitinib 50 mg (grade 2 left ventricular ejection fraction decline and grade 3 fatigue), and 37.5 mg was declared the MTD. Thirteen patients treated at the MTD achieved a partial response (objective response rate: 37%; 95% confidence interval, 22–55) and 12 (34%) had stable disease. Median progression-free survival was 11 months (95% confidence interval, 6–17). The most commonly reported grade 3/4 treatment-related adverse event was diarrhea (14%), the only grade 3/4 adverse event to occur in >2 patients. Pharmacokinetic analyses did not indicate any drug–drug interactions. Conclusions: In metastatic RCC, sunitinib plus gefitinib demonstrated comparable efficacy to sunitinib monotherapy with an acceptable safety profile. Dosing, pharmacokinetic profile, and safety support study of sunitinib plus an epidermal growth factor receptor inhibitor in other tumor types." @default.
• W1994839562 created "2016-06-24" @default.
• W1994839562 creator A5010671566 @default.
• W1994839562 creator A5012346270 @default.
• W1994839562 creator A5012997413 @default.
• W1994839562 creator A5021595416 @default.
• W1994839562 creator A5059063118 @default.
• W1994839562 creator A5063926652 @default.
• W1994839562 creator A5066291048 @default.
• W1994839562 creator A5083158555 @default.
• W1994839562 date "2010-12-01" @default.
• W1994839562 modified "2023-10-17" @default.
• W1994839562 title "Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma" @default.
• W1994839562 cites W2016757878 @default.
• W1994839562 cites W2104540972 @default.
• W1994839562 cites W2105677187 @default.
• W1994839562 cites W2105984177 @default.
• W1994839562 cites W2129417849 @default.
• W1994839562 cites W2139248078 @default.
• W1994839562 cites W2145854263 @default.
• W1994839562 cites W2153331460 @default.
• W1994839562 cites W2156408558 @default.
• W1994839562 cites W2166788033 @default.
• W1994839562 cites W2258529761 @default.
• W1994839562 doi "https://doi.org/10.1097/coc.0b013e3181c4454d" @default.
• W1994839562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20142724" @default.
• W1994839562 hasPublicationYear "2010" @default.
• W1994839562 type Work @default.
• W1994839562 sameAs 1994839562 @default.
• W1994839562 citedByCount "25" @default.
• W1994839562 countsByYear W19948395622012 @default.
• W1994839562 countsByYear W19948395622013 @default.
• W1994839562 countsByYear W19948395622014 @default.
• W1994839562 countsByYear W19948395622015 @default.
• W1994839562 countsByYear W19948395622016 @default.
• W1994839562 countsByYear W19948395622017 @default.
• W1994839562 countsByYear W19948395622020 @default.
• W1994839562 countsByYear W19948395622021 @default.
• W1994839562 crossrefType "journal-article" @default.
• W1994839562 hasAuthorship W1994839562A5010671566 @default.
• W1994839562 hasAuthorship W1994839562A5012346270 @default.
• W1994839562 hasAuthorship W1994839562A5012997413 @default.
• W1994839562 hasAuthorship W1994839562A5021595416 @default.
• W1994839562 hasAuthorship W1994839562A5059063118 @default.
• W1994839562 hasAuthorship W1994839562A5063926652 @default.
• W1994839562 hasAuthorship W1994839562A5066291048 @default.
• W1994839562 hasAuthorship W1994839562A5083158555 @default.
• W1994839562 hasConcept C112705442 @default.
• W1994839562 hasConcept C121608353 @default.
• W1994839562 hasConcept C126322002 @default.
• W1994839562 hasConcept C126894567 @default.
• W1994839562 hasConcept C143998085 @default.
• W1994839562 hasConcept C159641895 @default.
• W1994839562 hasConcept C197934379 @default.
• W1994839562 hasConcept C2777288759 @default.
• W1994839562 hasConcept C2777472916 @default.
• W1994839562 hasConcept C2778820342 @default.
• W1994839562 hasConcept C2779438470 @default.
• W1994839562 hasConcept C2779490328 @default.
• W1994839562 hasConcept C2779984678 @default.
• W1994839562 hasConcept C2780580887 @default.
• W1994839562 hasConcept C31760486 @default.
• W1994839562 hasConcept C535046627 @default.
• W1994839562 hasConcept C71924100 @default.
• W1994839562 hasConcept C90924648 @default.
• W1994839562 hasConcept C98274493 @default.
• W1994839562 hasConceptScore W1994839562C112705442 @default.
• W1994839562 hasConceptScore W1994839562C121608353 @default.
• W1994839562 hasConceptScore W1994839562C126322002 @default.
• W1994839562 hasConceptScore W1994839562C126894567 @default.
• W1994839562 hasConceptScore W1994839562C143998085 @default.
• W1994839562 hasConceptScore W1994839562C159641895 @default.
• W1994839562 hasConceptScore W1994839562C197934379 @default.
• W1994839562 hasConceptScore W1994839562C2777288759 @default.
• W1994839562 hasConceptScore W1994839562C2777472916 @default.
• W1994839562 hasConceptScore W1994839562C2778820342 @default.
• W1994839562 hasConceptScore W1994839562C2779438470 @default.
• W1994839562 hasConceptScore W1994839562C2779490328 @default.
• W1994839562 hasConceptScore W1994839562C2779984678 @default.
• W1994839562 hasConceptScore W1994839562C2780580887 @default.
• W1994839562 hasConceptScore W1994839562C31760486 @default.
• W1994839562 hasConceptScore W1994839562C535046627 @default.
• W1994839562 hasConceptScore W1994839562C71924100 @default.
• W1994839562 hasConceptScore W1994839562C90924648 @default.
• W1994839562 hasConceptScore W1994839562C98274493 @default.
• W1994839562 hasIssue "6" @default.
• W1994839562 hasLocation W19948395621 @default.
• W1994839562 hasLocation W19948395622 @default.
• W1994839562 hasOpenAccess W1994839562 @default.
• W1994839562 hasPrimaryLocation W19948395621 @default.
• W1994839562 hasRelatedWork W1895933560 @default.
• W1994839562 hasRelatedWork W1994839562 @default.
• W1994839562 hasRelatedWork W2032144290 @default.
• W1994839562 hasRelatedWork W2064636609 @default.
• W1994839562 hasRelatedWork W2073298730 @default.
• W1994839562 hasRelatedWork W2103529332 @default.
• W1994839562 hasRelatedWork W2367626691 @default.
• W1994839562 hasRelatedWork W2590359217 @default.

• next